The European Statements of Hospital Pharmacy are a set of hospital pharmacy practice standards published by the European Association of Hospital Pharmacists (EAHP) for European health systems to ensure safe, effective and optimal use of medicines in collaboration with multidisciplinary teams. Keele University was commissioned to conduct a survey among European hospital pharmacists to establish a baseline to assess awareness of the Statements and to identify any barriers to their implementation. The survey was conducted from January 2015 to March 2015, spanning 16 languages and 34 countries. The survey consisted of three sections: ▸ Section A: general questions about the participant's hospital pharmacy, such as workforce skill-mix and number of beds served; ▸ Section B: questions about the current activity of pharmacists around each statement; ▸ Section C: questions about the hospital's readiness and ability to implement the statements. In section B, a value was allocated to each response to rate the degree to which they were able to comply with each statement (where 1=never able to comply, 5=always complied). In section C, they were asked to what degree they agreed with the question (1 for strongly disagree, 5 for strongly agree). A response of 1 or 2 was deemed to indicate some difficulty in complying with that statement-a 'negative response'. Where this was the case, the participant was given the option to provide a free text response explaining the reasons for this difficulty. The full results are discussed in a subsequent paper (). Overall, the response rate was 18%, but the variation in this was marked. 22 of the 34 countries had a response rate of over 30%. The methods used for this survey results informs the methodology and scope of future EAHP surveys Recommendations for future surveys are as follows: ▸ Keep the survey short and easy to complete (to within 20 min); ▸ Specifically enquire for each question if capacity and capability are the key barriers to implementation; ▸ Construct survey response options for each question to identify barriers other than capacity and capability; ▸ Identify the key drivers for change in countries where implementation has occurred or is occurring; ▸ Compile better intelligence about the number of surveys sent out in the first place (as those countries with a low response rate sent out lots of invites to participate which may be unrealistic); ▸ A named person (country coordinator) to send out invite survey link; ▸ Weekly reminders should be sent out by the named person (country coordinator).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451587 | PMC |
http://dx.doi.org/10.1136/ejhpharm-2016-000893 | DOI Listing |
Psychiatry Clin Psychopharmacol
December 2024
Department of Hematology, Chongqing University Three Gorges Hospital, Chongqing, China.
Background: This study was designed to determine the effects of acceptance and commitment care in the treatment of aplastic anemia (AA) patients with recombinant human thrombopoietin (rhTPO).
Methods: The clinical records of 100 AA patients treated at our hospital from March 2021 to March 2023 were analyzed in the retrospective study. All patients received immunosuppressants and rhTPO.
Viruses
November 2024
C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
SARS-CoV-2 infection induces a humoral immune response, producing virus-specific antibodies such as IgM, IgG, and IgA. IgA antibodies are present at mucosal sites, protecting against respiratory and other mucosal infections, including SARS-CoV-2, by neutralizing viruses or impeding attachment to epithelial cells. Since SARS-CoV-2 spreads through the nasopharynx, the specific IgAs of SARS-CoV-2 are produced quickly after infection, effectively contributing to virus neutralization.
View Article and Find Full Text PDFViruses
November 2024
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
Introduction: Variants of COVID-19 are responsible for 700 million infections and 7 million deaths worldwide. Vaccinations have high efficiency in preventing infection and secondary benefits of reducing COVID-19 hospital admissions, attenuating disease severity and duration of illness. Conflicting reports were published regarding COVID-19 among PLWH.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Henan Province Center for Disease Control and Prevention, Zhengzhou 450003, China.
Objectives: This study aimed to evaluate the immunogenicity and safety of a 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/TT) (PCV13i) in infants.
Methods: A total of 1200 infants were randomly assigned to either the experimental PCV13i group or the control PCV13 group in a 1:1 ratio. Each group received a three-dose series of the vaccine at 2, 4, and 6 months of age, followed by a booster dose at 12-15 months.
Vaccines (Basel)
December 2024
Vaccine Bio Research Institute, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.
Background: Varicella can lead to severe complications in immunocompromised children, including those undergoing hematopoietic stem cell transplantation (HSCT) or chemotherapy. Preventing primary varicella zoster virus (VZV) infection is crucial in these populations to mitigate morbidity and mortality. This study aimed to evaluate the immunogenicity and safety of the live attenuated MAV/06 varicella vaccine in pediatric patients post-HSCT and post-chemotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!